Table 3b.
Treatment details and outcomes of the included participants from cohort studies.
| Study ID | Intervention - palliative intent? | Surgery (no. of pts) | Chemotherapy - adjuvant/neoadjuvant/palliative (n/% of pts) | Radiotherapy - definitive, adjuvant or neoadjuvant (n/% of pts) | Hormonal therapy - adjuvant/neoadjuvant (n/% of pts) | Median FU duration (months) | Median survival (months) (range) | Final FU - Quality of life (% of pts) | LC (median months) |
|---|---|---|---|---|---|---|---|---|---|
| Abdallah (2022) | Yes | Mastectomy ± lymphadenectomy 81 | Adjuvant and neoadjuvant | No | Adjuvant | 18 (0–101) | Estimated mean OS: 55 (41.98–69.9) | NR | NR |
| Andersen (2009) | NR | No | Palliative | No | Concurrent 10 | NR | NR | NR | NR |
| Bichoo (2020) | No | Mastectomy 70 | - Neoadjuvant (84 %) - Adjuvant (10 %) |
- Neoadjuvant 4/59 - Adjuvant 47/59 - Palliative 8/59 |
Adjuvant 33 | 40 (2–93) | 36 | Ulcer healing | NR |
| Chia (2016) | NR | No | Palliative post-RT 42.9 % | Palliative | Palliative pre- and post-RT 23 | 11.7 | 11.7 (95 % CI 0.8–22.7) | 94.28 % achieved symptom palliation | 10 |
| Hoeltgen (2023) | NR | No | No | Palliative | No | 6.5 | 10.9 | - 95 % of pts achieved symptoms palliation - Reduction of analgesic intake in 28.6 % of pts |
4.7 |
| Kakagia (2004) | NR | No | Palliative | No | Palliative | NR | NR | Ulcer healing and returning to daily life in all pts | NR |
| La Verde (2013) | NR | No | Palliative | No | 12 | 8.7 | 9.1 (95 % CI: 7.0–not applicable) | - Worsening of KPS (median KPS: 80, range: 40–100) - Improvement of cutaneous symptoms |
NR |
| Merino (2015) | NR | 18 (11 mastectomy, 7 local excision) | NR | Palliative re-irradiation | 23 | 78.6 | NR | Symptomatic response after treatment: - Pain 83.33 % - Ulceration 44.44 % - Bleeding 16.66 % - Brachial plexus involvement 44.44 % - Lymphedema 27.77 % - Bad odor 11.11 % |
28.9 |
| Shaugnessy (2015) | NR | 4 | Concurrent with radiation | Both definitive and palliative | No | 25.3 (range: 1.6–42 months) | NR | NR | 11.2 (range: 8–27.1) |
| Vempati (2016) | NR | NR | NR | NR | NR | NR | 4.6 for prior RT group, 4.5 for naïve group. Median survival for both groups 4.5 | - 50 % of pts from the group with prior RT experienced benefit from the palliative treatment and - 42.85 % of pts from the RT-naïve group experienced benefit from the palliative treatment. - 69 % of pts who received 30 Gy or more reported clinical improvement, whereas none of the 4 pts who received less than 30 Gy reported any benefit. |
NR |
Data are reported when available as number (%) or mean (range). Abbreviations: Pts: patients, DCIS: ductal carcinoma in situ, IDC: infiltrative ductal carcinoma, ILC: infiltrative lobular carcinoma, NR: not reported, FU: follow-up, LC: local control, RT: radiotherapy treatment.